A potential primary endpoint for clinical trials in glaucoma ...

The LiGHT study explored the use of selective laser trabeculoplasty (SLT) as a first-line therapy for treatment-naïve patients with primary open ...

Phase 3 Randomized Clinical Trial of the Safety and Efficacy of ...

The travoprost intraocular implant demonstrated robust IOP reduction over the 3-month primary efficacy evaluation period after a single administration. The IOP- ...

Glaucoma Clinical Research Trials | CenterWatch

Background: Primary open angle glaucoma (OAG) is a chronic progressive neurodegenerative disease where intraocular pressure (IOP) is the main and successfully ...

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of ...

The bimatoprost implant met the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months after the ...

Visual field endpoints based on subgroups of points may be useful ...

Visual Field Endpoints for Neuroprotective Trials

Progression of VF loss is an important clinical endpoint in glaucoma, particularly when assessing the efficacy of treatments. The Federal Drug ...

The Ocular Hypertension Treatment Study: A Randomized Trial ...

Background Primary open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and worldwide. Three to 6 million people in the ...

Designs and Methodologies Used in Landmark Clinical Trials of ...

Recently, the 10th World Glaucoma Association (WGA) Consensus Meeting supported the use of optic nerve structural endpoints alone to provide sufficient ...

Glaucoma Clinical Trials | Ophthalmology | U of U School of Medicine

The Moran Eye Center regularly conducts clinical trials to advance glaucoma care. Below is a list of our current glaucoma trials.

Glaucoma: neuroprotection with NAD-based therapeutic interventions

Clinical evidence shows that intraocular hypertension is not the primary pathogenetic event of glaucoma, whereas early neurodegeneration of ...

Glaucoma Fort Worth | Research - Ophthalmology Associates

Sponsor: Ivantis Inc. A Phase 2 Prospective, Multicenter, Randomized, Double-Masked Clinical Trial to Evaluate the Safety, Efficacy, and Dose-Response of the ...

Clinical Trials | Ophthalmology - Stanford Medicine

Clinical Trials · A Randomized, Sham Controlled, Masked Phase II Study to Evaluate the Safety and Efficacy of Dual Intravitreal Implantation of NT-501 ...

Proposed LCD - Micro-Invasive Glaucoma Surgery (MIGS) (DL38301)

While the outcome of progression of glaucoma is the final endpoint given the benefits of lowering IOP as reported in this study they do not feel a control group ...

Assessment of the Impact of an Endpoint Committee in the Ocular ...

4 Almost all National Eye. Institute–sponsored clinical trials of ocular hypertension and glaucoma have used visual fields as a primary endpoint, including ...

Ciliatech presents clinical trial results from SAFARI III glaucoma study

Results indicate the CID works similarly for patients with primary open angle glaucoma (POAG) and primary angle closure glaucoma (PACG), also ...

Glaucoma Rehabilitation using ElectricAI Transcranial Stimulation ...

Glaucoma patients with irreversible visual field loss often experience decreased quality of life, impaired mobility, and mental health ...

Incorporating Glaucoma Clinical Trials into Clinical Decision Making

Glaucoma clinical trials influence medical, laser and surgical decision making for the clinician. During this live webinar, we will review ...

Priority Research Areas: Opportunities for Donations to Drive ...

Project 1: Angle closure glaucoma is a leading cause of blindness worldwide with limited evidence supporting current treatments. The team will: Continue an ...

A Review of the Most Impactful Glaucoma Studies - Modern Optometry

The Collaborative Normal-Tension Glaucoma Study (CNTGS) found that a 30% reduction in IOP helped prevent progression of NTG. A faster rate of progression was ...

iSTAR Medical initiates international STAR-VI trial for the use of ...

The primary endpoint of the trial is to measure the proportion of patients achieving a ≥20% reduction in diurnal intraocular pressure (IOP) ...